Profits reached Rs 658.88 crore compared to Rs 511.18 crore earned during the same period last year. Total revenue rose by 13.6% to Rs 3,076.51 crore, up from Rs 2,708.10 crore the previous year.
“The company had a ‘steady revenue growth of 13.6 per cent year-on-year with strong EBITDA margins of 27.7 per cent, driven by recovery in volume, continued outperformance in chronic segment and operating leverage,’” said Rajeev Juneja, Vice Chairman and Managing Director.
Domestic sales within India increased by 11% to reach ₹2,796 crore while exports saw significant growth, jumping 57% to ₹281 crore. Mankind Pharma stated this was “driven by an increase in our base business supported by new launches in the last 12-24 months.”
Domestic brokerage firm Motilal Oswal has increased its target price on Mankind to Rs 3,140 by valuing the stock at 45x 12M forward earnings.
“We tweak our earnings estimates (-3.7%/3.0% for FY26/FY27) factoring in: a) addition of business from the BSV acquisition, b) sustained growth prospects in exports, and c) a scale-up in the consumer healthcare business,” it said.
